Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17699940 | 0.86 | SLC6A1 (0.47) | SLC6A1TSHRSLC6A11SLC6A13LMNA | |
| SCHEMBL27905543 | 0.85 | SLC6A2 (0.43) | SLC6A1TSHRSLC6A11SLC6A13SLC6A2 | |
| SCHEMBL5023299 | 0.85 | SLC6A2 (0.43) | SLC6A1TSHRSLC6A11SLC6A13SLC6A2 | |
| SCHEMBL27905533 | 0.85 | SLC6A2 (0.43) | SLC6A1TSHRSLC6A11SLC6A13SLC6A2 | |
| SCHEMBL14723183 | 0.81 | GABRA5 (0.46) | SLC6A1TSHRSLC6A11SLC6A13LMNA | |
| SCHEMBL25306928 | 0.79 | SLC6A4 (0.49) | SLC6A1TSHRSLC6A11SLC6A13LMNA | |
| SCHEMBL4167603 | 0.79 | SLC6A4 (0.49) | SLC6A1TSHRSLC6A11SLC6A13LMNA | |
| SCHEMBL3235890 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4E | |
| SCHEMBL6800002 | 0.76 | LMNA (0.38) | LMNACYP2D6CHRNA7KMT2A | |
| SCHEMBL6800001 | 0.76 | LMNA (0.38) | LMNACYP2D6CHRNA7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101312979-A | Pyrimidine compounds for the treatment of inflammatory disorders | CELLZOME UK LTD (GB) | 2008-11-26 | — | — | CN | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | SLC6A1 4197/4885TSHR 2954/4885SLC6A11 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.